1. Generics Bulletin
  2. >>Business

What Does Teva’s Exit From PhRMA Suggest About Its Priorities?

Teva Insists Its Memberships And Investments Must Be ‘Properly Seated’

 
• By Dean Rudge

Seemingly in one of the first decisions overseen by the company’s new CEO Richard Francis, Teva will not sit at the table of the US brand industry trade association, the Pharmaceutical Research and Manufacturers of America, better known as PhRMA.

Exit
How will Teva approach its novel pipeline under Francis? • Source: Shutterstock

With an entrenched hybrid business model and novel assets in its pipeline, Teva has called time on its membership with the powerful US brand industry trade association, the Pharmaceutical Research and Manufacturers of America, or PhRMA, after six-and-a-half years.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.